Corbion stock holds as FY 2025 revenue reached EUR 1.07 billion

Corbion (NL0010583399) is anchored by FY 2025 revenue of EUR 1.07 billion, adjusted EBITDA of EUR 153.0 million and net debt of EUR 515 million at 31 December 2025. Those are the core numbers investors can actually measure, and they frame the share more than any short-term market noise.

FY 2025 revenue at EUR 1.07 billion

For FY 2025, Corbion reported revenue of EUR 1.07 billion and adjusted EBITDA of EUR 153.0 million, according to its 2025 annual reporting. Net debt stood at EUR 515 million at year-end 2025, which matters because it shows how much balance-sheet room the company had after a full-year earnings cycle.

The comparison is clear enough: revenue in FY 2025 was up from EUR 1.05 billion in FY 2024, while adjusted EBITDA rose from EUR 146.0 million. That puts the operating trend on a firmer footing than a flat headline would suggest.

Margin and debt matter

Corbion also reported an adjusted EBITDA margin of 14.3% in FY 2025, compared with 13.9% in FY 2024. For a food-and-biochemicals company, that kind of margin progression is often more important than a single quarter's top-line print.

Net debt of EUR 515 million at 31 December 2025 gives a second anchor for valuation work. In a business with industrial exposure and working-capital swings, the debt line can move the equity story as much as revenue does.

Products still feed the story

Corbion's product mix still revolves around ingredients and biobased solutions, with its business model tied to applications in food preservation, lactic acid and specialty ingredients. That matters because the reported full-year figures show how those segments convert into EBITDA and cash generation over a 12-month period.

For investors, the key point is not product branding but conversion: EUR 1.07 billion of revenue, EUR 153.0 million of adjusted EBITDA and EUR 515 million of net debt at 31 December 2025 form the basic valuation frame.

Stock closing frame

Corbion stock is traded on Euronext Amsterdam in euros, and the latest report numbers provide the most concrete operating frame available in this article. The share should be read against FY 2025 revenue, EBITDA and leverage rather than as a pure momentum trade.